The approval for the drug, which will be sold under the brand name Foundayo, marks an important technological inflection point for this class of drugs that is transforming obesity care in the US and around the world
Actualmente hay al menos 39 nuevos frmacos GLP-1 en desarrollo
However, in some cases, persistent or severe gastrointestinal symptoms may necessitate dose adjustment, switching to an alternative GLP-1 agent, or discontinuation of therapy
Do not aim it at the powder
14 Diabetes Management A 2021 review 15 emphasizes that for people newly diagnosed with type 2 diabetes, healthy lifestyle changesincluding proper nutrition and regular physical exerciseshould be the primary line of treatment
The GLP-1s are indeed special, says Dr